DHR vs PFE
DHR: A diversified conglomerate applying advanced technologies and quality manufacturing across life sciences, diagnostics, environmental & applied solutions, and industrial products. PFE: Global biopharmaceutical company discovering, developing, and manufacturing prescription medicines and vaccines across oncology, immunology, cardiovascular, and infectious disease.
Side-by-side fundamentals
| Metric | DHR | PFE | Edge |
|---|---|---|---|
| Price as of 2026-07-09 close | $195.98 | $24.25 | |
| Market cap as of 2026-07-10 | $137.8B | $138.1B | |
| P/E as of 2026-07-10 | 37.35 | 18.44 | PFE lower |
| PEG as of 2026-07-10 | 3.97 | -3.38 | PFE lower |
| Net margin as of 2026-07-10 | +14.9% | +11.8% | DHR higher |
| Gross margin as of 2026-07-10 | +59.0% | +74.8% | PFE higher |
| Operating margin as of 2026-07-10 | +19.2% | +15.4% | DHR higher |
| ROE as of 2026-07-10 | +7.1% | +8.4% | PFE higher |
| ROA as of 2026-07-10 | +4.5% | +3.6% | DHR higher |
| Debt / equity as of 2026-07-10 | 0.35 | 0.72 | DHR lower |
| Revenue growth (YoY) as of 2026-07-10 | +4.0% | +1.4% | DHR higher |
| Revenue CAGR (3y) SEC XBRL | -2.7% | -14.8% | DHR higher |
| Dividend yield as of 2026-07-10 | +0.8% | +7.1% | PFE higher |
| Dividend streak (yrs) SEC XBRL | n/a | 5 | |
| Beta as of 2026-07-10 | 0.78 | 0.29 | |
| 1-year return as of 2026-07-09 close | -4.9% | -5.1% | DHR higher |
Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.